People who inject drugs represent approximately 90% of newly acquired hepatitis C infections. Clinicians in primary care and drug and alcohol settings play an important role in improving the health outcomes of people living with hepatitis C and can reduce a patient’s risk of developing advanced liver disease through early diagnosis, appropriate management of co-morbidities and treatment with new, curative, Direct Acting Antiviral medication (DAAs).
This interactive course is designed to strengthen the capacity of clinical staff working in primary care or drug and alcohol settings to effectively test for, treat and manage hepatitis C.
The online learning and face-to-face workshop will give you the skills to confidently prescribe the new Direct Acting Antiviral (DAA) medications for hepatitis C.
This course is free. Registration is essential. Lunch and refreshments will be provided.
This activity has been approved by the RACGP QI&CPD Program for 40 Category 1 CPD points, and by ACRRM for 30 PRPD points.
This workshop has been supported through an undconditional grant from Gilead Sciences Pty Ltd.
